America’s New Most Expensive Drug Reignites Debate Over How to Price Gene Therapies

doctor-looking-in-microscope
December 8

The FDA on Nov. 22 approved Hemgenix (etranacogene dezaparvovec-drlb), the first gene therapy for adults with hemophilia B, a genetic bleeding disorder. CSL Behring, the medication’s commercial rights holder, set a list price of $3.5 million, making it the most expensive drug in the U.S.

That price exceeds the $2.96 million health benefit price threshold (HBPB) that the nonprofit Institute for Clinical and Economic Review (ICER) determined recently in an evidence report, meaning it is not cost-effective according to the nonprofit’s guidelines.

0
0 Comments
© 2023 MMIT
Tim Casey

Tim Casey

Tim has worked as a reporter and editor for more than 20 years. Before joining AIS Health in December 2021, he was a business reporter covering the commercial real estate industry’s capital markets for four years. He previously covered health care business issues for two medical publishing companies and high school, college and professional sports for the Sacramento Bee newspaper. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.

Related Posts

nurse-and-patient-in-wheelchair
November 10

Cell and Gene Therapies Hold Promise, but Stakeholders Must Overcome Challenges to Meet Their Full Potential

READ MORE
scientists-studying-genes
October 27

Novel Therapies Take Center Stage in Optum Rx Drug Pipeline Report

READ MORE
iv-drip
August 25

FDA Approves Gene Therapy, Manufacturer Prices Drug at Record $2.8 Million

READ MORE
panalgo-building-an-effective-analytics-team

The Latest

Premium Categories

directory-of-health-plans-test-drive-directory-of-health-plans-ad

Meet Our Reporters

Tags

Benefit ManagementDrug PricingSpecialty DrugsSpecialty Pharmacy

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today